Halozyme develops and licenses drug-delivery technology that enables large-volume biologics to be given as subcutaneous injections instead of intravenous infusions. Its ENHANZE platform is based on a recombinant human hyaluronidase enzyme and is used in partnered products across oncology and other specialty areas. Revenue is driven largely by royalties, milestones and supply agreements with major pharmaceutical companies rather than a broad proprietary drug portfolio.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 264.9 | — | 118.1 | 17.7% |
| Q2 2025 | 325.7 | — | 165.2 | 41.6% |
| Q3 2025 | 354.3 | — | 175.2 | 8.9% |
| Q4 2025 | 451.8 | — | -141.6 | -188.3% |
| Q1 2026 | 376.7 | 42.2% | 150.1 | 27.1% |
| Q2 2026 | 481 | 47.7% | 229.9 | 39.2% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: IES Holdings, Inc. (IESC), DraftKings Inc. (DKNG), Jack Henry & Associates, Inc. (JKHY), Li Auto Inc. (LI), Amkor Technology, Inc. (AMKR), Maplebear Inc. (CART)